This IDC study discusses how digital transformation accurately characterizes the life science industry's ongoing efforts to transform itself as it seeks to find new paths to innovation, optimize operational efficiency and effectiveness, and regain long-term sustainability. As in other industries, the digital transformation journey begins with a common definition of the mission, strategic priorities, and programs so that individual projects or use cases can better align with a life science company's overall goals and objectives.
"Digital transformation continues to transform patient and HCP engagement and fuel innovation in the life science industry. With the increasing adoption of newer technologies such as federated learning platforms, prescription digital therapeutics, and the metaverse, including AR, VR, and MR, it is essential to have a clear understanding of the digital taxonomy for life sciences and to be cognizant of the use cases where these disruptive technologies are being applied," says Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology, IDC Health Insights.
"Digital transformation in the life science industry is moving forward rapidly. 3rd Platform technologies such as cloud, mobile, big data and analytics, and social data are already woven into the life science commercial arena. Emerging technologies like AI and RPA are accelerating productivity for commercial teams by maximizing message impact and relevance while reducing duplicate or confusing interactions with HCPs. In life science supply chains, IoT networks and platforms are enabling tracking and monitoring of sensitive and rare biologic drugs, allowing rapid deployment to patients in critical need around the globe. From the manufacturing floor to doctors' offices, digital technology is improving quality, efficiency, and patient experience," says Michael Townsend, research director, Commercial Life Sciences, IDC Health Insights.